Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab with High-Dose Therapy and Autologous Stem Cell Transplant in CLL
NCT00276809Phase 2Completed
- Sponsor
- German CLL Study Group
- Start
- Jun 2001
- Primary completion
- Sep 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by German CLL Study Group. Started Jun 2001; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00276809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276809.